Eagle Pharmaceuticals Inc (EGRX.OQ)
EGRX.OQ on NASDAQ Stock Exchange Global Market
79.13USD
20 Aug 2018
79.13USD
20 Aug 2018
Change (% chg)
$0.99 (+1.27%)
$0.99 (+1.27%)
Prev Close
$78.14
$78.14
Open
$78.74
$78.74
Day's High
$79.61
$79.61
Day's Low
$77.58
$77.58
Volume
54,450
54,450
Avg. Vol
86,032
86,032
52-wk High
$85.66
$85.66
52-wk Low
$48.94
$48.94
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Jun '18 | 59.30 | 0.172 |
| Mar '18 | 46.63 | 0.169 | |
| FY 2017 | Dec '17 | 46.78 | 0.801 |
| Sep '17 | 63.02 | 0.979 | |
| Jun '17 | 50.11 | 0.280 | |
| Mar '17 | 76.79 | 1.418 | |
| FY 2016 | Dec '16 | 81.14 | 3.530 |
| Sep '16 | 37.83 | 0.727 | |
| Jun '16 | 40.92 | 0.796 | |
| Mar '16 | 29.59 | -0.057 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 5 | 55.41 | 59.90 | 52.90 | 58.30 |
| Quarter Ending Dec-18 | 5 | 60.94 | 62.70 | 58.30 | 62.00 |
| Year Ending Dec-18 | 5 | 222.28 | 228.10 | 217.10 | 216.10 |
| Year Ending Dec-19 | 5 | 257.98 | 275.71 | 243.90 | 283.83 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 5 | 0.99 | 1.12 | 0.74 | 1.05 |
| Quarter Ending Dec-18 | 5 | 1.40 | 1.53 | 1.10 | 1.21 |
| Year Ending Dec-18 | 5 | 3.87 | 4.07 | 3.31 | 3.51 |
| Year Ending Dec-19 | 5 | 4.77 | 5.52 | 3.86 | 5.31 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 9.78 | 30.93 | 32.76 | |
| P/E High - Last 5 Yrs. | -- | 40.66 | 45.44 | |
| P/E Low - Last 5 Yrs. | -- | 23.69 | 24.26 | |
| Beta | 1.23 | 0.90 | 0.89 | |
| Price to Sales (TTM) | 3.59 | 3.94 | 5.75 | |
| Price to Book (MRQ) | 5.34 | 4.88 | 5.00 | |
| Price to Tangible Book (MRQ) | 9.43 | 5.70 | 6.57 | |
| Price to Cash Flow (TTM) | 8.87 | 22.85 | 23.29 | |
| % Owned Institutions | -- | 1.23 | 2.21 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.57 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 1.58 | 1.52 | |
| Dividend 5 Year Growth Rate | -- | 4.35 | 5.22 | |
| Payout Ratio(TTM) | 0.00 | 45.85 | 43.78 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 22.46 | 2.27 | 8.01 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 160.39 | 4.77 | 5.64 | |
| Sales - 5 Yr. Growth Rate | -- | 9.94 | 10.18 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -64.84 | 17.61 | 20.60 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 3,637.76 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 9.75 | 10.66 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 15.37 | 15.34 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 3.76 | 2.15 | 2.22 |
| Current Ratio (MRQ) | 3.88 | 2.94 | 3.03 |
| LT Debt to Equity (MRQ) | 0.00 | 10.03 | 12.51 |
| Total Debt to Equity (MRQ) | 0.00 | 14.07 | 16.85 |
| Interest Coverage (TTM) | -- | 35.77 | 32.63 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 75.17 | 54.71 | 54.37 | |
| Gross Margin - 5 Yr. Avg. | -- | 52.10 | 52.17 | |
| EBITD Margin (TTM) | 33.38 | -- | -- | |
| EBITD - 5 Yr. Avg | -- | 18.48 | 10.65 | |
| Operating Margin (TTM) | 32.21 | 14.31 | 4.32 | |
| Operating Margin - 5 Yr. Avg. | -- | 14.43 | 6.06 | |
| Pre-Tax Margin (TTM) | 32.20 | 14.80 | 5.18 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | 14.82 | 6.49 | |
| Net Profit Margin (TTM) | 39.32 | 11.05 | 1.48 | |
| Net Profit Margin - 5 Yr. Avg. | -- | 11.12 | 2.77 | |
| Effective Tax Rate (TTM) | -22.12 | 23.22 | 23.11 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.48 | 23.97 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 3,193,182 | 952,976,482 | 860,375,103 | |
| Net Income/Employee (TTM) | 1,255,584 | 112,117,219 | 101,207,184 | |
| Receivable Turnover (TTM) | 4.67 | 5.72 | 5.87 | |
| Inventory Turnover (TTM) | 12.27 | 2.63 | 3.41 | |
| Asset Turnover (TTM) | 1.33 | 0.96 | 0.94 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 52.32 | 11.58 | 11.13 | |
| Return on Assets - 5 Yr. Avg. | -- | 12.95 | 12.40 | |
| Return on Investment (TTM) | 64.07 | 15.07 | 14.61 | |
| Return on Investment - 5 Yr. Avg. | -- | 16.90 | 16.13 | |
| Return on Equity (TTM) | 70.78 | 16.59 | 16.33 | |
| Return on Equity - 5 Yr. Avg. | -- | 17.97 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 186.11 | -- | -- |
| EPS (TTM) % | 3,033.35 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eagle Pharmaceuticals Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture
- BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53
- BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln
- BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA
- BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 254 |
| Total Shares Held: | 15,774,871 |
| 3 Mo. Net Change: | -446,428 |
| # New Positions: | 35 |
| # Closed Positions: | 25 |
| # Increased Positions: | 110 |
| # Reduced Positions: | 92 |
| # Net Buyers: | 18 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.